Skip to main content
FDA Updates
Lonsurf (Trifluridine plus Tipiracil): A New Oral Treatment Approved for Patients with Metastatic Colorectal Cancer
Lisa A. Raedler, PhD, RPh, Medical Writer
Read More
FDA Updates
Welcome to the First Annual Oncology Pharmacy Guide to New FDA Approvals
Read More
FDA Updates
Imlygic (Talimogene Laherparepvec): First Oncolytic Viral Therapy for the Treatment of Patients with Recurrent Melanoma
Lisa A. Raedler, PhD, RPh, Medical Writer
Read More
FDA Updates
Imbruvica (Ibrutinib): First Drug Approved for the Treatment of Patients with Waldenström’s Macroglobulinemia
Lisa A. Raedler, PhD, RPh, Medical Writer
Read More
FDA Updates
Empliciti (Elotuzumab): First SLAMF7 Antibody Therapy Approved for the Treatment of Patients with Previously Treated Multiple Myeloma
Lisa A. Raedler, PhD, RPh, Medical Writer
Read More
FDA Updates, Monoclonal Antibodies
Darzalex (Daratumumab): First Anti-CD38 Monoclonal Antibody Approved for Patients with Relapsed Multiple Myeloma
Lisa A. Raedler, PhD, RPh, Medical Writer
Read More
FDA Updates
Bendeka (Bendamustine Hydrochloride): Rapid-Infusion Formulation Approved for Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphomas
Lisa A. Raedler, PhD, RPh, Medical Writer
Read More
FDA Updates, Tyrosine Kinase Inhibitor
Alecensa (Alectinib), an Oral Tyrosine Kinase Inhibitor, Approved for Metastatic Non–Small-Cell Lung Cancer with ALK Mutation
Read More
FDA Updates
FDA Approvals of Brand-Name Prescription Drugs in 2015
Read More
FDA Updates
Translation of Benchtop Science Arrives in Force, Improves Patient Care
Val R. Adams, PharmD, BCOP, FCCP, FHOPA
Read More
Page 175 of 200
Results 1741 - 1750 of 1993